Summit Therapeutics Inc. Variable Lease, Cost
Summit Therapeutics Inc. (SMMT) reported Variable Lease, Cost of $225.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-02-23
- Summit Therapeutics Inc. variable lease, cost for the quarter ending 2023-12-31 was $12.00K, a 73.91% decline year-over-year.
- Summit Therapeutics Inc. variable lease, cost for the quarter ending 2023-09-30 was $2.00K, a 96.23% decline year-over-year.
- Summit Therapeutics Inc. variable lease, cost for the quarter ending 2023-06-30 was $26.00K, a 7.14% decline year-over-year.
- Summit Therapeutics Inc. variable lease, cost for the quarter ending 2023-03-31 was $43.00K, a 330.00% increase year-over-year.
- Summit Therapeutics Inc. variable lease, cost for fiscal 2025 was $225.00K, a 368.75% increase from fiscal 2024.
- Summit Therapeutics Inc. variable lease, cost for fiscal 2024 was $48.00K, a 42.17% decline from fiscal 2023.
- Summit Therapeutics Inc. variable lease, cost for fiscal 2023 was $83.00K, a 39.42% decline from fiscal 2022.
- Summit Therapeutics Inc. variable lease, cost for fiscal 2022 was $137.00K, a 16.46% decline from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $225.00K 10-K · filed 2026-02-23 | |||
| 2024-12-31 | $48.00K 10-K · filed 2026-02-23 | |||
| 2023-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $14.00K derived: sum of 2 quarters · filed 2026-02-23 | $40.00K derived: sum of 3 quarters · filed 2026-02-23 | $83.00K 10-K · filed 2026-02-23 |
| 2023-09-30 | $2.00K 10-Q · filed 2023-11-07 | $28.00K derived: sum of 2 quarters · filed 2023-11-07 | $71.00K 10-Q · filed 2023-11-07 | $117.00K derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-06-30 | $26.00K 10-Q · filed 2023-08-09 | $69.00K 10-Q · filed 2023-08-09 | $115.00K derived: sum of 3 quarters · filed 2025-02-24 | $168.00K derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-03-31 | $43.00K 10-Q · filed 2023-05-11 | $89.00K derived: sum of 2 quarters · filed 2025-02-24 | $142.00K derived: sum of 3 quarters · filed 2025-02-24 | $170.00K derived: sum of 4 quarters · filed 2025-02-24 |
| 2022-12-31 | $46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $99.00K derived: sum of 2 quarters · filed 2025-02-24 | $127.00K derived: sum of 3 quarters · filed 2025-02-24 | $137.00K 10-K · filed 2025-02-24 |
| 2022-09-30 | $53.00K 10-Q · filed 2023-11-07 | $81.00K derived: sum of 2 quarters · filed 2023-11-07 | $91.00K 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $28.00K 10-Q · filed 2023-08-09 | $38.00K 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $10.00K 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $164.00K 10-K · filed 2023-03-09 | |||
| 2020-12-31 | $171.00K 10-K/A · filed 2022-12-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |